GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » EV-to-FCF

Bio View (XTAE:BIOV) EV-to-FCF : 29.05 (As of May. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Bio View EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio View's Enterprise Value is ₪24.84 Mil. Bio View's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.86 Mil. Therefore, Bio View's EV-to-FCF for today is 29.05.

The historical rank and industry rank for Bio View's EV-to-FCF or its related term are showing as below:

XTAE:BIOV' s EV-to-FCF Range Over the Past 10 Years
Min: -625.35   Med: 9.47   Max: 104.39
Current: 28.74

During the past 13 years, the highest EV-to-FCF of Bio View was 104.39. The lowest was -625.35. And the median was 9.47.

XTAE:BIOV's EV-to-FCF is ranked worse than
50.7% of 357 companies
in the Medical Devices & Instruments industry
Industry Median: 28.4 vs XTAE:BIOV: 28.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Bio View's stock price is ₪0.287. Bio View's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.005. Therefore, Bio View's PE Ratio for today is 57.40.


Bio View EV-to-FCF Historical Data

The historical data trend for Bio View's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View EV-to-FCF Chart

Bio View Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.78 80.86 12.01 70.52 -253.15

Bio View Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.88 -29.80 70.52 40.08 -253.15

Competitive Comparison of Bio View's EV-to-FCF

For the Medical Devices subindustry, Bio View's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio View's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio View's EV-to-FCF falls into.



Bio View EV-to-FCF Calculation

Bio View's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=24.842/0.855
=29.05

Bio View's current Enterprise Value is ₪24.84 Mil.
Bio View's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio View  (XTAE:BIOV) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bio View's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.287/0.005
=57.40

Bio View's share price for today is ₪0.287.
Bio View's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.005.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bio View EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bio View's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio View (XTAE:BIOV) Business Description

Traded in Other Exchanges
N/A
Address
3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View (XTAE:BIOV) Headlines

No Headlines